| First Author | Schere-Levy C | Year | 2022 |
| Journal | Int J Mol Sci | Volume | 23 |
| Issue | 7 | PubMed ID | 35409002 |
| Mgi Jnum | J:323197 | Mgi Id | MGI:7262263 |
| Doi | 10.3390/ijms23073642 | Citation | Schere-Levy C, et al. (2022) Treatment with Angiotensin-(1-7) Prevents Development of Oral Papilloma Induced in K-ras Transgenic Mice. Int J Mol Sci 23(7) |
| abstractText | Oral Squamous Cell Carcinoma (OSCC) is the most common malignant cancer affecting the oral cavity. It is characterized by high morbidity and very few therapeutic options. Angiotensin (Ang)-(1-7) is a biologically active heptapeptide, generated predominantly from AngII (Ang-(1-8)) by the enzymatic activity of angiotensin-converting enzyme 2 (ACE 2). Previous studies have shown that Ang-(1-7) counterbalances AngII pro-tumorigenic actions in different pathophysiological settings, exhibiting antiproliferative and anti-angiogenic properties in cancer cells. However, the prevailing effects of Ang-(1-7) in the oral epithelium have not been established in vivo. Here, we used an inducible oral-specific mouse model, where the expression of a tamoxifen-inducible Cre recombinase (CreER(tam)), which is under the control of the cytokeratin 14 promoter (K14-CreER(tam)), induces the expression of the K-ras oncogenic variant KrasG12D (LSLK-ras(G12D)). These mice develop highly proliferative squamous papilloma in the oral cavity and hyperplasia exclusively in oral mucosa within one month after tamoxifen treatment. Ang-(1-7) treated mice showed a reduced papilloma development accompanied by a significant reduction in cell proliferation and a decrease in pS6 positivity, the most downstream target of the PI3K/Akt/mTOR signaling route in oral papilloma. These results suggest that Ang-(1-7) may be a novel therapeutic target for OSCC. |
